retatrutide phase 3 trial Eli Lilly obesity results 2026 Retatrutide Shows 28.3% Weight Loss

Encourages expression of feelings to identify the need for information and support and to dismiss guilt and anxiety

Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes

GIP and GLP1 are neuroprotective in preclinical models of neurodegenerative disease

Activating these receptors improves fat metabolism, may protect bone density (a critical concern for lupus patients on corticosteroids), and provides additional cardiovascular benefits

Formulation Choice and Route of Administration Semaglutide is available as compounded injection or oral formulation

P., Moreno, J